Cordarone

Pacerone

1. Blocks sodium, potassium, and calcium channels
2. Prolongs the action potential and repolarization
3. Decreases AV conduction and Sinoatrial (SA) node function.

1. Stable Narrow Complex Tachycardia if rhythm persists despite vagal maneuvers, adenosine, or the tachycardia is recurrent to control ventricular rate in stable, irregular narrow complex tachycardia (e.g. AF)
2. To control ventricular rate in pre-excited atrial dysrhythmias with conduction over accessory pathways
3. Stable monomorphic VT
4. Polymorphic VT with normal QT interval
5. Cardiac arrest resulting from VF or pulseless VT after CPR and defibrillation

1. known hypersensitivity
2. Cardiogenic Shock
3. Second or third degree AV block
4. Sick Sinus Syndrome or other sinus node disease unless a functioning artificial pacemaker present

1. Dizziness
2. Fatique
3. Malaise
4. Tremors
5. Ataxia
6. Lack of coordination
7. ARDS
8. Pulmonary Edema
9. Cough
10. Progressive Dyspnea
11. Heart Failure
12. Bradycardia
13. Hypertension
14. Worsening Dysrhythmias
15. Prolonged QT intervals
16. Nausea
17. Vomiting
18. Burning at IV site
19. Steven Johnson Syndrome

1. Use with Digoxin may cause digitalis toxicity
2. Beta-blockers and calcium channel blockers may potentiate bradycardia, sinus arrest and AV blocks

Adult:

VF/Pulseless VT: 300 mg IV/IO push. Initial dose can be followed once in 3-5 minutes at 150 mg IV/IO over 10 minutes; may repeat every 10 minutes if need.

After conversion, follow with 1 mg/minute infusion for 6 hours, then a 0.5 mg/minute maintenance infusion for 18 hours.

Max cumulative dose: 2.2 g IV/IO per 24 hours

Pediatric:

Refactory VF/Pulseless VT: 5 mg/kg IV/IO bolus. Can repeat the 5 mg/kg IV/IO bolus up to total dose of 15 mg/kg per 24 hrs. (2.2 g in adolescents).

Max single dose: 300 mg

Perfusing ventricular or atrial dysrhythmia loading dose 15 mg/kg per day, (2.2 g in adolescents)

• onset: Immediate
• Peak: 10 - 15 Minutes
• Duration: 30 - 45 Minutes